Capital Impact Advisors, LLC Arvinas, Inc. Transaction History

Capital Impact Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $648,327 - $932,216	-17,821 Reduced 58.37%	12,710 $524,000
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $374,016 - $540,973	17,212 Added 129.23%	30,531 $757,000
Q1 2023 May 23, 2023	BUY	$26.15 - $37.26 $138,072 - $196,732	5,280 Added 65.68%	13,319 $363,000
Q3 2022 Nov 21, 2022	BUY	$41.87 - $57.99 $29,518 - $40,882	705 Added 9.61%	8,039 $426,000
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $264,097 - $544,476	7,334 New	7,334 $309,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.